Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Trial Profile

Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Ravulizumab (Primary)
  • Indications Haemolytic uraemic syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 27 Jul 2017 According to an Alexion Pharmaceuticals media release, company expects to complete enrollment in this trial in early 2018.
    • 27 Apr 2017 According to an Alexion Pharmaceuticals media release, patients are being dosed in this trial.
    • 16 Feb 2017 According to an Alexion Pharmaceuticals media release, company expects to complete enrollment in this trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top